United States securities and exchange commission logo





                               March 16, 2021

       Zheng Wei, Ph.D.
       Chief Executive Officer
       Connect Biopharma Holdings Limited
       Science and Technology Park
       East R&D Building, 3rd Floor
       6 Beijing West Road, Taicang
       Jiangsu Province, China 215400

                                                        Re: Connect Biopharma
Holdings Limited
                                                            Amendment No. 1 to
Registration Statement on Form F-1
                                                            Filed March 12,
2021
                                                            File No. 333-253631

       Dear Dr. Wei:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form F-1

       General

   1.                                                   We note that the tax
opinion filed as Exhibit 8.2 appears to be a short-form tax opinion.
                                                        Please have counsel
revise the opinion to clearly identify that the "Taxation     People's
                                                        Republic of China
Taxation" disclosure is the opinion of the counsel. Please also revise
                                                        the opinion to provide
the consent of counsel to being named in the registration
                                                        statement. For
guidance, refer to Sections III.B.2 and IV of Staff Legal Bulletin No. 19.
   2.                                                   Please revise the
arbitration provisions in Exhibit 10.2 to clearly state that they do not
                                                        apply to claims under
the Securities Act or the Exchange Act.
 Zheng Wei, Ph.D.
Connect Biopharma Holdings Limited
March 16, 2021
Page 2

       You may contact Eric Atallah at 202-551-3663 or Vanessa Robertson at
202-551-3649 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Ada D. Sarmento at 202-551-3798 or Tim Buchmiller at 202-551-3635 with
any other
questions.



                                                          Sincerely,
FirstName LastNameZheng Wei, Ph.D.
                                                          Division of
Corporation Finance
Comapany NameConnect Biopharma Holdings Limited
                                                          Office of Life
Sciences
March 16, 2021 Page 2
cc:       Patrick A. Pohlen, Esq.
FirstName LastName